GlassScriptPhysician profile
Taylor Ann Stocker
NPI 1326799016
$5,339.47
in general payments reported to CMS, 2019-2025
20 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,740 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,095 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,095.48 |
| Education | $243.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $733.81 | 2024-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $723.20 | 2024-2025 | |
| Amgen INC. | $720.21 | 2024-2025 | Krystexxa, Otezla, Tavneos |
| Ani Pharmaceuticals, INC. | $667.11 | 2024-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $434.50 | 2024-2025 | Orencia |
| Ucb, INC. | $391.25 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $367.62 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $334.64 | 2024-2025 | |
| Genzyme Corporation | $231.80 | 2024-2025 | |
| Organon LLC | $154.16 | 2024-2025 | Hadlima, Renflexis |
| Janssen Scientific Affairs, LLC | $107.47 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $89.04 | 2024-2025 | Benlysta |
| Sobi, INC | $82.90 | 2024-2025 | |
| Radius Health, INC. | $80.78 | 2025 | Tymlos |
| Fresenius Kabi USA, LLC | $71.79 | 2024-2025 | Idacio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.57 | 2024-2025 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $38.66 | 2025 | Opsumit, Uptravi |
| Aurinia Pharma U.S., INC. | $24.58 | 2025 | Lupkynis |
| Genentech USA, INC. | $20.99 | 2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $19.39 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Stocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.